Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 4Lymphoma 2Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Glioblastoma 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 58Cisplatin 41Capecitabine 27Oxaliplatin 25durvalumab 16Fluorouracil 16Leucovorin 15S 1 (combination) 11lenvatinib 10Nivolumab 10Irinotecan 10pembrolizumab 8apatinib 8Immune Checkpoint Inhibitors 7130-nm albumin-bound paclitaxel 7tremelimumab 6Bevacizumab 6camrelizumab 5Trastuzumab 5Drug Therapy 5Blood Specimen Collection 5Albumin-Bound Paclitaxel 5tislelizumab 4irinotecan sucrosofate 4Taxes 4Liquid Biopsy 4Folfox protocol 4toripalimab 3surufatinib 3gemcitabine-oxaliplatin regimen 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Biliary Tract Neoplasms × manganese chloride × Clear all
NCT04004234 2019-07-09

A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

Chinese PLA General Hospital

Phase 1/2 Unknown
20 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡